Vol 25, No 1-2 (2023)
Review paper
Published online: 2024-09-13
Diagnosis and therapy of optic pathway gliomas. Literature review
DOI: 10.5603/chp.95315
Chirurgia Polska 2023;25(1-2):38-47.
Abstract
Optic pathway gliomas (OPGs) are low-grade primary neoplasms of the central nervous system, most common in children and young adults. OPG may occur sporadically or in the course of neurofibromatosis type 1. The clinical image may vary depending on the location and size of the tumor. OPG can be asymptomatic as well as give ophthalmic symptoms such as single-sided extortion or visual disturbances. Although gliomas of the visual pathway are low-grade tumors, their behavior can be aggressive and their treatment is often challenging. The treatment for these tumors is highly individualized. depending on the nature and extent of the lesion and the visual function. May include conservative observation, chemotherapy, radiotherapy or surgical intervention.
Keywords: optic nerve gliomaneurofibromatosis 1diagnosistreatment
References
- Farazdaghi MK, Katowitz WR, Avery RA. Current treatment of optic nerve gliomas. Curr Opin Ophthalmol. 2019; 30(5): 356–363.
- Rasool N, Odel JG, Kazim M. Optic pathway glioma of childhood. Curr Opin Ophthalmol. 2017; 28(3): 289–295.
- Park ES, Park JB, Ra YS. Pediatric glioma at the optic pathway and thalamus. J Korean Neurosurg Soc. 2018; 61(3): 352–362.
- Nair AG, Pathak RS, Iyer VR, et al. Optic nerve glioma: an update. Int Ophthalmol. 2014; 34(4): 999–1005.
- Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol. 2018; 33(1): 73–81.
- Aihara Y, Chiba K, Eguchi S, et al. Pediatric optic pathway/hypothalamic glioma. Neurol Med Chir (Tokyo). 2018; 58(1): 1–9.
- Dodge HW, Love JG, Craig WM. Gliomas of the optic nerves. AMA Arch Neurol Psychiatry. 1958; 79(6): 607–621.
- Fried I, Tabori U, Tihan T, et al. Optic pathway gliomas: a review. CNS Oncol. 2013; 2(2): 143–159.
- Shapey J, Danesh-Meyer HV, Kaye AH. Diagnosis and management of optic nerve glioma. J Clin Neurosci. 2011; 18(12): 1585–1591.
- Purohit BS, Vargas MI, Ailianou A, et al. Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging. Insights Imaging. 2016; 7(1): 43–68.
- Cassina M, Frizziero L, Opocher E, et al. Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations. Cancers (Basel). 2019; 11(11).
- Sellmer L, Farschtschi S, Marangoni M, et al. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis. 2018; 13(1): 62.
- Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007; 61(3): 189–198.
- Trevisson E, Cassina M, Opocher E, et al. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. J Neurooncol. 2017; 134(2): 279–287.
- Blanchard G, Lafforgue MP, Lion-François L, et al. NF France network. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol. 2016; 20(2): 275–281.
- Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997; 41(2): 143–149.
- Evans DG, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res. 2017; 23(12): e46–e53.
- Prada CE, Hufnagel RB, Hummel TR, et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr. 2015; 167(4): 851–856.e1.
- Chung EM, Specht CS, Schroeder JW. From the archives of the AFIP: Pediatric orbit tumors and tumorlike lesions: neuroepithelial lesions of the ocular globe and optic nerve. Radiographics. 2007; 27(4): 1159–1186.
- Becker M, Masterson K, Delavelle J, et al. Imaging of the optic nerve. Eur J Radiol. 2010; 74(2): 299–313.
- Cummings TJ, Provenzale JM, Hunter SB, et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol. 2000; 99(5): 563–570.
- Barkovich AJ. Pediatric neuroimaging, 4th edn. Lippincott Williams & Wilkins, Philadelphia 2005: 875–884.
- Weber AL, Caruso P, Sabates NR. The optic nerve: radiologic, clinical, and pathologic evaluation. Neuroimaging Clin N Am. 2005; 15(1): 175–201.
- Pungavkar SA, Lawande MA, Patkar DP, et al. Bilateral optic pathway glioma with intracranial calcification: magnetic resonance imaging and magnetic resonance spectroscopy findings. Australas Radiol. 2005; 49(6): 489–492.
- Pepin SM, Lessell S. Anterior visual pathway gliomas: The last 30 years. Semin Ophthalmol. 2006; 21(3): 117–124.
- Miller NR. Primary tumours of the optic nerve and its sheath. Eye (Lond). 2004; 18(11): 1026–1037.
- Wilhelm H. Primary optic nerve tumours. Curr Opin Neurol. 2009; 22(1): 11–18.
- Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol. 1994; 38(5): 427–452.
- Ge M, Li S, Wang L, et al. The role of diffusion tensor tractography in the surgical treatment of pediatric optic chiasmatic gliomas. J Neurooncol. 2015; 122(2): 357–366.
- Yeom KW, Lober RM, Andre JB, et al. Prognostic role for diffusion-weighted imaging of pediatric optic pathway glioma. J Neurooncol. 2013; 113(3): 479–483.
- Parrozzani R, Clementi M, Kotsafti O, et al. Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Vis Sci. 2013; 54(13): 8112–8118.
- Parrozzani R, Miglionico G, Leonardi F, et al. Correlation of peripapillary retinal nerve fibre layer thickness with visual acuity in paediatric patients affected by optic pathway glioma. Acta Ophthalmol. 2018; 96(8): e1004–e1009.
- Avery RA, Mansoor A, Idrees R, et al. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1. Neurology. 2016; 87(23): 2403–2407.
- Avery RA, Cnaan A, Schuman JS, et al. Longitudinal change of circumpapillary retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol. 2015; 160(5): 944–952.e1.
- Liu Y, Hao X, Liu W, et al. Analysis of survival prognosis for children with symptomatic optic pathway gliomas who received surgery. World Neurosurg. 2018; 109: e1–e15.
- Avery RA, Fisher MJ, Liu GT. Optic pathway gliomas. J Neuroophthalmol. 2011; 31(3): 269–278.
- Liu GT. Optic gliomas of the anterior visual pathway. Curr Opin Ophthalmol. 2006; 17(5): 427–431.
- Borghei-Razavi H, Shibao S, Schick U. Prechiasmatic transection of the optic nerve in optic nerve glioma: technical description and surgical outcome. Neurosurg Rev. 2017; 40(1): 135–141.
- Reddy AT, Witek K. Neurologic complications of chemotherapy for children with cancer. Curr Neurol Neurosci Rep. 2003; 3(2): 137–142.
- Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012; 14(6): 790–797.
- Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer. 2010; 46(12): 2253–2259.
- Pollack IF. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr. 2011; 8(2): 135–148.
- Koutourousiou M, Gardner PA, Kofler JK, et al. Rare infundibular tumors: clinical presentation, imaging findings, and the role of endoscopic endonasal surgery in their management. J Neurol Surg B Skull Base. 2013; 74(1): 1–11.
- Walker DA, Liu J, Kieran M, et al. CPN Paris 2011 Conference Consensus Group. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol. 2013; 15(4): 462–468.
- El Beltagy MA, Reda M, Enayet A, et al. Treatment and outcome in 65 children with optic pathway gliomas. World Neurosurg. 2016; 89: 525–534.
- Goodden J, Pizer B, Pettorini B, et al. The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr. 2014; 13(1): 1–12.
- Mohammad AEN. En-Bloc resection versus resection after evacuation and suction of the content for orbital optic nerve glioma causing visual loss and disfiguring proptosis. Ophthalmic Plast Reconstr Surg. 2020; 36(4): 399–402.
- Kaderbhai J, Lo W, Rodrigues D, et al. Craniofacial approaches to pediatric orbital tumors. J Craniofac Surg. 2019; 30(4): 1198–1200.
- van Baarsen K, Roth J, Serova N, et al. Optic pathway-hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. J Neurosurg. 2018; 129(6): 1407–1415.
- Kondo A, Akiyama O, Suzuki M, et al. A novel surgical approach for intraorbital optic nerve tumors. J Clin Neurosci. 2019; 59: 362–366.
- Stella I, Helleringer M, Joud A, et al. Optic pathway tumor in children: toward a new classification for neurosurgical use. Neurochirurgie. 2021; 67(4): 336–345.
- Shofty B, Ben-Sira L, Kesler A, et al. Optic pathway gliomas. Adv Tech Stand Neurosurg. 2015; 42: 123–146.
- Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009; 24(11): 1397–1408.
- Ahn Y, Cho BK, Kim SK, et al. Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst. 2006; 22(9): 1136–1142.
- Mishra MV, Andrews DW, Glass J, et al. Characterization and outcomes of optic nerve gliomas: a population-based analysis. J Neurooncol. 2012; 107(3): 591–597.
- Shriver EM, Ragheb J, Tse DT. Combined transcranial-orbital approach for resection of optic nerve gliomas: a clinical and anatomical study. Ophthalmic Plast Reconstr Surg. 2012; 28(3): 184–91.
- Numa Y, Kawamoto K. Frontozygomatic approach to intraorbital tumors. Skull Base. 2007; 17(5): 303–310.
- Zoli M, Mazzatenta D, Valluzzi A, et al. Expanding indications for the extended endoscopic endonasal approach to hypothalamic gliomas: preliminary report. Neurosurg Focus. 2014; 37(4): E11.
- Somma T, Solari D, Beer-Furlan A, et al. Endoscopic endonasal management of rare sellar lesions: clinical and surgical experience of 78 cases and review of the literature. World Neurosurg. 2017; 100: 369–380.
- Bin Abdulqader S, Al-Ajlan Z, Albakr A, et al. Endoscopic transnasal resection of optic pathway pilocytic astrocytoma. Childs Nerv Syst. 2019; 35(1): 73–81.
- Graffeo CS, Dietrich AR, Grobelny B, et al. A panoramic view of the skull base: systematic review of open and endoscopic endonasal approaches to four tumors. Pituitary. 2014; 17(4): 349–356.
- Kasemsiri P, Carrau RL, Ditzel Filho LFS, et al. Advantages and limitations of endoscopic endonasal approaches to the skull base. World Neurosurg. 2014; 82(6 Suppl): S12–S21.
- Stapleton AL, Tyler-Kabara EC, Gardner PA, et al. Risk factors for cerebrospinal fluid leak in pediatric patients undergoing endoscopic endonasal skull base surgery. Int J Pediatr Otorhinolaryngol. 2017; 93: 163–166.
- Chivukula S, Koutourousiou M, Snyderman CH, et al. Endoscopic endonasal skull base surgery in the pediatric population. J Neurosurg Pediatr. 2013; 11(3): 227–241.
- Giovannetti F, Mussa F, Priore P, et al. Endoscopic endonasal skull base surgery in pediatric patients. A single center experience. J Craniomaxillofac Surg. 2018; 46(12): 2017–2021.
- Ater J. Results of COG protocol A9952 : a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol. 2008; 10: 451.
- Ater JL, Xia C, Mazewski CM, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the children's oncology group. Cancer. 2016; 122(12): 1928–1936.
- Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012; 30(12): 1358–1363.
- Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study. J Clin Oncol. 2016; 34(29): 3537–3543.
- Devereux S, Selassie TG, Vaughan Hudson G, et al. Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ. 1990; 301(6760): 1077–1080.
- Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica. 1999; 84(10): 937–945.
- Perry JR, Brown MT, Gockerman JP. Acute leukemia following treatment of malignant glioma. J Neurooncol. 1998; 40(1): 39–46.
- Maris JM, Wiersma SR, Mahgoub N, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer. 1997; 79(7): 1438–1446.
- Matsui I, Tanimura M, Kobayashi N, et al. Neurofibromatosis type 1 and childhood cancer. Cancer. 1993; 72(9): 2746–2754, doi: 10.1002/1097-0142(19931101)72:9<2746::aid-cncr2820720936>3.0.co;2-w.
- Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994; 330(9): 597–601.
- Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994; 70(5): 969–972.
- Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002; 20(20): 4209–4216.
- Cardellicchio S, Bacci G, Farina S, et al. Low-dose cisplatin-etoposide regimen for patients with optic pathway glioma: a report of four cases and literature review. Neuropediatrics. 2014; 45(1): 42–49.
- Cappellano AM, Petrilli AS, da Silva NS, et al. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol. 2015; 121(2): 405–412.
- Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007; 9(2): 161–168.
- Banerjee A, Jakacki RI, Onar-Thomas A, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017; 19(8): 1135–1144.
- Bartels U, Hawkins C, Jing Ma, et al. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg. 2006; 104(5 Suppl): 314–320.
- Presta LG, Chen H. O’Connor SJ, at al. Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders. Cancer Res. 1997; 57(20): 4593–4599.
- Gururangan S, Fangusaro J, Poussaint TY, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium Study. Neuro Oncol. 2014; 16(2): 310–317.
- Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013; 60(5): 776–782.
- Falsini B, Chiaretti A, Rizzo D, et al. Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial. Brain. 2016; 139(Pt 2): 404–414.
- Warrington NM, Gianino SM, Jackson E, et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res. 2010; 70(14): 5717–5727.
